New hope for liver cancer: experimental drug targets tough cases
Disease control
Recruiting now
This study tests an experimental drug called AST-3424 in people with advanced liver cancer that has a specific marker (AKR1C3-high) and has worsened after immunotherapy. About 75 participants will receive either AST-3424 or a standard drug (regorafenib) to see which helps them li…
Phase: PHASE2 • Sponsor: Zhejiang Hisun Pharmaceutical Co. Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC